Drug industry analysts and other observers couldn't be faulted for asking, "Haven't we heard this before?" after Pfizer Inc. on Oct. 10 said it is considering selling is consumer health business.
Pfizer Déjà Vu: Is It Time To Sell The Consumer Health Business?
As Pfizer re-examines a potential sale of its consumer business, analysts expect it would attract suitors for its unit, with $15bn to $17bn a likely price, but also say it might be better off continuing to compete in the sector that accounted for around $3.4bn of its 2016 revenues.
More from International
More from Geography
Offer valuing struggling UK consumer health player Alliance at £350m has the backing of the company's board of directors.
In response to an IPA Europe complaint, European Ombudsman Emily O’Reilly finds that the Commission’s interpretation of EU food legislation in relation to probiotics is “reasonable and in line with the main goal of this legislation, which is to ensure a high level of consumer protection.”
Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.